Publication
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerAcute Myeloid Leukemiacivic_curation1.00
- drugGilteritinibcivic_curation1.00
- geneFLT3civic_curation1.00
- variantFLT3 D835civic_curation1.00
- variantFLT3 I836civic_curation1.00
- variantFLT3 ITDcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31665578
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FLT3 D835 + FLT3 I8361 | ||||||||
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12622In a phase 3 trial comparing gilteritinib (120 mg/day) to salvage chemotherapy (SC) in adults with relapsed or refractory FLT3- mutated AML, patients were required to have FLT3 ITD or TKD (tyrosine ki… (full text at CIViC) PMID 31665578 · Perl et al., 2019 · Open in CIViC | civic |
| FLT3 ITD1 | ||||||||
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12621In a phase 3 trial comparing gilteritinib (120 mg/day) to salvage chemotherapy (SC) in adults with relapsed or refractory FLT3- mutated AML, patients were required to have FLT3 ITD or TKD (tyrosine ki… (full text at CIViC) PMID 31665578 · Perl et al., 2019 · Open in CIViC | civic |
| FLT3 D835 + FLT3 I836 + FLT3 ITD2 | ||||||||
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11260In this phase III, randomized trial, 371 patients with Relapsed or Refractory FLT3-Mutated AML were randomized 2:1 to receive either gilteritinib (at a dose of 120 mg per day) or salvage chemotherapy.… (full text at CIViC) PMID 31665578 · Perl et al., 2019 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID7728In this phase 3 trial (ADMIRAL), 371 patients with relapsed or refractory FLT3-mutated AML (required to have FLT3 ITD or TKD D835 or I836 mutations) were randomly assigned in a 2:1 ratio to receive ei… (full text at CIViC) PMID 31665578 · Perl et al., 2019 · Open in CIViC | civic |